Dear Colleagues,
Here is the Daily Briefing for 17 May 2017.
Any feedback would be most welcome.
Best wishes,
Faraz Kermani, Communications Manager (External Affairs)

Companies

- **Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China**
  (16/05/2017) (World Pharma News)
The site, in Zhang Jiang Hi-tech Park of Shanghai, enjoys a first-phase investment of over €70 million, and is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilising mammalian cell culture technology.

Infectious Diseases

- **WHO prepares experimental Ebola vaccine for possible use in DRC**
  (16/05/2017) (STAT)
The WHO and outside experts are making arrangements to send an experimental Ebola vaccine to the Democratic Republic of Congo, should officials there say they need it to quell an outbreak there.

IP

- **IP-Watch Guide To 2017 World Health Assembly: Election, Budget, Antibiotics, Cancer, R&D And More**
  (16/05/2017) (Intellectual Property Watch)
The 70th World Health Assembly will open its doors in Geneva with a marathon agenda, and over 4,000 registered delegates. The election of a new director general, the approval of the budget for the next biennium (2018/2019) are set to capture the attention of member states.
Generics

**Lupin launches erectile dysfunction drug Cialis - (Business Standard via NewsPoints Desk)**
(16/05/2017) (FirstWord Pharma)
Lupin has launched a generic version of Eli Lilly's erectile dysfunction treatment Cialis in India through an exclusive licensing agreement with the US company.

Health Services

**Labour calls for inquiry into NHS cyber-attack**
(16/05/2017) (British Medical Journal)
Politicians and doctors’ leaders have called for an official inquiry into the “ransomware” cyber-attack that paralysed IT systems across 48 English NHS trusts, 13 NHS organisations in Scotland, general practices, and pharmacies on 12 May.

Legal Affairs

**CVS's Omnicare to pay $8 million to settle U.S. probe**
(17/05/2017) (Reuters Health & Fitness News)
CVS Health Corp's Omnicare unit has agreed to pay $8 million to resolve claims that its prescription verification system resulted in false claims being submitted to government healthcare programmes.

E-Health/Apps/Devices

**Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland**
(17/05/2017) (British Medical Journal)
Self sourced medical abortion using online telemedicine can be highly effective, and outcomes compare favourably with in clinic protocols.

**Unlocking the Mystery of Multiple Sclerosis With Tech**
(16/05/2017) (FirstWord Pharma)
Recruitment begins for a Keck School of Medicine of USC study of the first smartphone app to combine clinical data, MRI imaging and genetic data for people with multiple sclerosis.

Specific Disease Areas

**Surveillance and Colorectal Cancer Risk in Patients With Intermediate-Risk Adenomas**
(16/05/2017) (The Asco Post)
A UK retrospective study showed that colonoscopic surveillance was associated with a reduced risk of colorectal cancer among patients with removal of intermediate-risk adenomas.

Regulatory

**VIBERZI Now Approved in Canada for patients with irritable bowel syndrome with diarrhea (IBS-D)**
(16/05/2017) (FirstWord Pharma)
Allergan’s Viberzi (eluxadoline) is approved by Health Canada approval for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
**Pharmaceutical Industry**

- **Big pharma hopes rule change will ease China sales pain**
  
  The world’s largest pharmaceutical companies, which are struggling with pricing pressures in China, are hoping that wider access to drugs and a faster approval process will boost sales.

**Patients**

- **Physician age and patient outcomes**
  
  Researchers have shown that patients of older hospitalists had higher odds of 30 day in hospital mortality than patients of younger hospitalists.

**Innovation**

- **Stem cell therapies: can anything stop them now?**
  
  With a global society of researchers, regulators and clinicians celebrating its 25th anniversary, 2017 is a good time to consider how cellular therapies have progressed in this period.

**Mental Health**

- **Cuba looks to begin trials of new neuroprotective treatment for Alzheimer's**
  
  Cuba’s Center for Molecular Immunology has announced that it will be putting through an Alzheimer’s treatment through clinical testing, subject to approval by the Center for Drug Control Equipment and Medical Devices.

**Counterfeiting**

- **Survey Suggests that One-Third of Pharma Companies Aren't Ready for Serialization**
  
  Although deadlines for serialization are only a few months away, a recent survey suggests that 36% of pharmaceutical manufacturers and contract packagers are not preparing to meet global serialisation requirements.

**Brexit**

- **Brexit’s potential health benefits**
  
  Brexit will have significant disruptive effects on medicines regulation and the future of the pharmaceutical industry, but it also offers some potential advantages if politicians and policymakers commit firmly to an alternative course.
Google unit DeepMind's access to 1.6 million NHS patients' data deemed inappropriate

(16/05/2017) (FirstWord Pharma)

According to the National Data Guardian, the most senior data protection adviser to the NHS, Google's DeepMind unit received the personally identifying medical records of 1.6 million NHS patients on an "inappropriate legal basis".